NV-UECTEL-WIRELESS
10.1.2024 18:01:36 CET | Business Wire | Press release
CES 2024 – Quectel Wireless Solutions, a global IoT solutions provider, and Morse Micro, the leading Wi-Fi HaLow silicon vendor, today announced that the Quectel FGH100M Wi-Fi HaLow module has received CE certification for Europe and Federal Communications Commission (FCC) certification for the US. The CE and FCC certification of the module, powered by Morse Micro’s MM6108 SoC, underscores the rigorous testing and compliance with the highest standards of safety, health, and environmental protection required in the European Area, while the certification by the FCC also means that the module is approved for use in electronic devices sold in the United States.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240110233128/en/
Quectel and Morse Micro Introduce the Industry’s First Wi-Fi HaLow Module to Achieve European CE and US FCC Certifications at CES 2024 (Photo: Business Wire)
The certification represents a crucial step in expanding the market reach of Wi-Fi HaLow technology and enabling its deployment in a wide range of Wi-Fi HaLow and IoT applications across multiple geographic regions. This industry first achievement not only underscores Wi-Fi HaLow technology’s readiness for the global market, but also solidifies the protocol’s position as a leading communications standard.
"Wi-Fi HaLow technology represents the future of global connectivity, and receiving both the CE mark and FCC certification is a testament to the reliability, safety, and interoperability Wi-Fi HaLow modules," said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "Our collaboration with Morse Micro has been crucial in achieving this milestone and other industry certifications."
The Wi-Fi HaLow module is designed for extended range and lower power consumption, making it ideal for numerous IoT applications, from smart homes and industrial automation to agricultural technology and beyond. With this certification, Quectel and Morse Micro are poised to lead the charge in long-range, low-power IoT connectivity, offering best-in-class Wi-Fi CERTIFIED HaLow solutions that meet the demands of today’s connected world.
"The Morse Micro team has been working tirelessly this year to expand the global reach of our Wi-Fi HaLow solutions, and that day has finally come with the achievement of CE certification for our module products,” said Prakash Guda, Vice President of Marketing and Product Management at Morse Micro. "By securing European CE certification for Wi-Fi HaLow modules, Quectel and Morse Micro have demonstrated the standard’s global acceptance. It’s a major leap forward in establishing Wi-Fi HaLow as a universal standard for IoT and wireless connectivity."
Operating in the sub-GHz frequency band, the Wi-Fi HaLow 802.11ah standard was designed from the ground up for the IoT, offering an optimal combination of extended range, power efficiency, long battery life for wireless devices, superior penetration of barriers, large network capacity, advanced security, and Wi-Fi compatibility.
Quectel’s IoT modules are developed with security at the core. From product architecture to firmware/software development, Quectel incorporates leading industry practices and standards, mitigating potential vulnerabilities with third party independent test houses and have incorporated security practices like generating SBOMs and VEX files as well as performing firmware binary analysis into the entire software development lifecycle
Quectel offers a range of antennas for the FGH100M LoRa module, including the YCIS001AA, YCIS002AA, YCIS003AA, YFNP017WWA, YPCS002BA, YMCP003AA, YEIN002AA, YECN028AA and YECW000N1A, enabling flexibility and compatibility to meet diverse project requirements.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
About Morse Micro
Morse Micro is a leading Wi-Fi HaLow fabless semiconductor company based in Sydney, with global offices. As the world's premier Wi-Fi HaLow company, we pioneer next-gen IoT wireless connectivity solutions. Morse Micro is now sampling its Wi-Fi Alliance and FCC-certifiable MM6108 production silicon: the fastest, smallest, lowest power and longest-range Wi-Fi HaLow chip available in the market. Learn more at https://www.morsemicro.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240110233128/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom